Impact News +++ Google and Samsung bet again on smart glasses, this time with Android XR (Digitimes) +++ SAMSUNG VZ Aktie +3,17%

NERVGEN Aktie

>NERVGEN Aktienkurs

5.125 EUR (Tradegate)

Ask: 5.2 EUR / 574 Stück

Bid: 5.05 EUR / 597 Stück

Tagesumsatz: 0 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

NERVGEN Aktie über LYNX handeln

Intraday

1 Jahr

>NERVGEN Performance

1 Woche: +15,2%

1 Monat: +40,4%

3 Monate: +76,1%

6 Monate: +125,2%

1 Jahr: +140,4%

laufendes Jahr: +15,2%

>NERVGEN Aktie

Name:

NERVGEN PHARMA CORP.

Land:

Kanada

Sektor:

Gesundheit

ISIN/ Wkn:

CA64082X2032 / A2QP3D

Symbol/ Ticker:

9UA (Frankfurt)

Kürzel:

FRA:9UA, ETR:9UA, 9UA:GR

Index:

Webseite:

https://nervgen.com/

Profil:

Nervgen Pharma Corp. is a biotechnology company fo..
>Volltext..

Marktkapitalisierung:

395.31 Mio. EUR

Unternehmenswert:

388.34 Mio. EUR

Umsatz:

EBITDA:

-15.61 Mio. EUR

Nettogewinn:

-15.86 Mio. EUR

Gewinn je Aktie:

-0.22 EUR

Schulden:

0.02 Mio. EUR

Liquide Mittel:

6.98 Mio. EUR

Operativer Cashflow:

-10.29 Mio. EUR

Bargeldquote:

0.71

Umsatzwachstum:

Gewinnwachstum:

0.86%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

NERVGEN

Letzte Datenerhebung:

09.01.26

>NERVGEN Kennzahlen

Aktien/ Unternehmen:

Aktien: 79.59 Mio. St.

Frei handelbar: 78.17%

Leerverk. Aktien: -

Rückkaufquote: -1.15%

Mitarbeiter: -

Umsatz/Mitarb.: -

Analysten:

Analystenrating: Buy

Kursziel: 3.05%

Bewertung:

KGV: -

KGV lG: -

KUV: -

KBV: -

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: -

Gewinnmarge: -

Operative Marge: -

Managementeffizenz:

Gesamtkaprendite: -145.3%

Eigenkaprendite: -827.94%

>NERVGEN Peer Group

Es sind 178 Aktien bekannt.

>NERVGEN Chart & Kurs - Tradegate

>NERVGEN News

08.01.26 - 12:33	NervGen Pharma Begins Trading on Nasdaq Today (GlobeNewswire EN)
	NervGen Pharma's common shares have been approved for listing on Nasdaq and will begin trading today, under the symbol "NGEN"...

17.12.25 - 22:30	NervGen Pharma Corp.: NervGen Pharma Announces Filing of Form F-10 Registration Statement with The SEC Under MJDS (Newsfile)
	Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a clinical-stage biopharmaceutical company develo......

13.12.25 - 02:06	NervGen Pharma Corp.: NervGen Pharma Announces Proposed Amendment to Warrants (Newsfile)
	Vancouver, British Columbia--(Newsfile Corp. - December 12, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a clinical-stage biopharmaceutical company develo......

24.11.25 - 13:27	NervGen Pharma GAAP EPS of -$0.06 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

24.11.25 - 13:18	NervGen Pharma Corp.: NervGen Pharma Reports Third Quarter Financial Results and Provides Business Updates (Newsfile)
	Expanded CONNECT SCI Study data demonstrated unprecedented durable improvement in function, independence, and quality of life in individuals living with chronic spinal cord injuryCompleted a U.S. ......

24.11.25 - 13:06	NervGen Pharma Corp.: NervGen Pharma Announces Expanded CONNECT SCI Study Data Demonstrating Unprecedented Durable Improvement in Function, Independence, and Quality of Life in Chronic Spinal Cord Injury (Newsfile)
	Week 16 follow-up data, coupled with blinded exit interviews conducted up to 364 days after the study period, confirm durable and wide-ranging upper and lower-body improvements compared to placebo......

19.11.25 - 22:42	NervGen Pharma Corp.: NervGen Pharma Announces Closing of US$10 Million Non-Brokered Private Placement to Support Anticipated Nasdaq Listing and Advance NVG-291 Development (Newsfile)
	Vancouver, British Columbia--(Newsfile Corp. - November 19, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a clinical-stage biopharmaceutical company develo......

18.11.25 - 23:09	NervGen Pharma announces $10M non-brokered private placement (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

18.11.25 - 22:54	NervGen Pharma Corp.: NervGen Pharma Announces US$10 Million Non-Brokered Private Placement to Support Anticipated Nasdaq Listing and Advance NVG-291 Development (Newsfile)
	Vancouver, British Columbia--(Newsfile Corp. - November 18, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a clinical-stage biopharmaceutical company develo......

26.08.25 - 13:42	NervGen Pharma Corp.: NervGen Pharma Reports Second Quarter Financial Results and Provides Letter to Shareholders (Newsfile)
	Announced unprecedented Phase 1b/2a topline results in chronic spinal cord injury NVG-291 is the first pharmacologic candidate to demonstrate statistically significant improvement in corticospinal......

21.08.25 - 13:42	NervGen Pharma Corp.: NervGen Pharma′s NVG-291-R Demonstrates Significant Functional Recovery in Department of Defense-Sponsored Preclinical Models of Traumatic Hearing Loss and Peripheral Nerve Injury (Newsfile)
	Demonstrated significant hearing restoration in blast-induced sensorineural hearing loss modelsPromoted significant functional recovery and axonal regeneration in peripheral nerve injury modelsRei......

17.07.25 - 13:51	NervGen Pharma announces CEO transition (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

17.07.25 - 13:48	NervGen Pharma Corp.: NervGen Announces Leadership Transition to Support Strategic Growth and Expansion (Newsfile)
	Vancouver, British Columbia--(Newsfile Corp. - July 17, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) (the "Company"), a clinical-stage biotechnology company developing innovative thera......

07.07.25 - 23:42	NervGen Pharma Corp.: NervGen Provides Quarterly "At-The-Market" Equity Program and Grant of Options Update (Newsfile)
	Vancouver, British Columbia--(Newsfile Corp. - July 7, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a clinical-stage biotech company dedicated to developi......

03.07.25 - 23:01	NervGen Pharma Corp.: NervGen Strengthens Board Leadership to Accelerate Clinical and Corporate Growth (Newsfile)
	Dr. Adam Rogers appointed chair as company advances toward key milestones following positive topline chronic cohort results of Phase 1b/2a CONNECT SCI StudyVancouver, British Columbia--(Newsfile C......

01.07.25 - 13:48	NervGen Pharma Corp.: NervGen Announces Clinical Leadership Transition as NVG-291 Continues to Advance Toward Late-Stage Development and Regulatory Milestones (Newsfile)
	Vancouver, British Columbia--(Newsfile Corp. - July 1, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neuroreparative therapeuti......

18.06.25 - 13:42	NervGen Pharma Corp.: NervGen Announces Appointment of Randall Kaye, MD to Chief Medical Advisor Role (Newsfile)
	Vancouver, British Columbia--(Newsfile Corp. - June 18, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neuroreparative therapeut......

21.05.25 - 13:43	NervGen Pharma Corp.: NervGen Pharma to Present Topline Data for NVG-291 Phase 1b/2a Chronic Cohort Study at the American Spinal Injury Association Annual Scientific Meeting (Newsfile)
	Vancouver, British Columbia--(Newsfile Corp. - May 21, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotechnology company dedicated to developing neuroreparative ther......

16.05.25 - 22:48	NervGen Pharma Corp.: NervGen Pharma Grants Stock Options (Newsfile)
	Vancouver, British Columbia--(Newsfile Corp. - May 16, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotechnology company dedicated to developing neuroreparative ther......

15.05.25 - 16:12	NervGen Pharma GAAP EPS of -$0.06 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Eine Frau, die ein Schöngeist ist, ist die Geißel ihres Mannes, ihrer Kinder, ihrer Freunde, ihres Gesindes und der ganzen Welt. - Jean-Jacques Rousseau

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram